Washington, D.C. — Former President Donald Trump revealed plans on Sunday to reintroduce a controversial drug pricing policy that seeks to align U.S. medication costs with those in other countries. The initiative aims to reduce expenses for certain pharmaceuticals but faces uncertainty regarding its implementation and potential impacts on drug access.

Trump’s earlier version of the policy, known as the “Most Favored Nation” rule, was established in late 2020 but was blocked by court rulings and ultimately rescinded by President Joe Biden in 2021. The original plan aimed to apply to Medicare payments for select drugs given in medical offices, yet details about which specific drugs would be affected by the new directive remain unclear.

In a post on Truth Social, Trump indicated that he plans to sign an executive order on Monday that he believes will significantly cut drug prices. He claimed the initiative could result in reductions of between 30% and 80%, applying a strategy where the U.S. would pay the same price as the country with the lowest pharmaceutical costs globally.

This proposal arrives during a period when Trump’s administration is also considering introducing tariffs on pharmaceutical imports, a shift from the previous exemption applied during his first term. Experts have raised concerns that these tariffs could lead to shortages of certain generic medications, ultimately increasing prices for consumers.

If the new executive order mirrors Trump’s initial rule, it might offer some financial relief to Medicare and its beneficiaries. However, there are apprehensions about potential limitations in patients’ access to necessary medications. The effectiveness of the policy will largely depend on its detailed design and execution.

Drug pricing had been a focal point during Trump’s initial presidency, though he had shifted his attention to other issues this term. Notably, some Republican leaders opposed the Most Favored Nation model, prompting his campaign to indicate a reduced focus on that approach last year.

Recently, the administration has reconsidered the policy as a possible avenue to meet substantial Medicaid spending cut targets outlined in the House GOP’s broader tax and spending reform agenda. The inclusion of this proposal in upcoming legislation remains uncertain.

The pharmaceutical industry is expected to mount vigorous opposition to this renewed initiative, having successfully thwarted its earlier incarnation. The original concept of connecting Medicare drug reimbursements to international prices first emerged in 2018, culminating in a finalized rule shortly after the 2020 election. This framework aimed to leverage discounts obtained by other nations, where medications typically cost less due to government intervention in pricing.

Under the 2020 proposal, Medicare was poised to pay the lowest price available among peer countries for 50 specific drugs administered in clinical settings, with estimated savings of around $86 billion over time.

While Medicare previously lacked the authority to negotiate drug prices directly, the 2022 Inflation Reduction Act changed that landscape, granting the program the power to negotiate prices annually for a limited number of drugs. Such negotiations could yield further savings for beneficiaries by affecting both out-of-pocket costs and premiums, which are influenced heavily by drug pricing structures.

The resurgence of the Most Favored Nation policy reflects ongoing debates over healthcare affordability and the balancing act between reducing costs and ensuring patient access to essential medications. The forthcoming executive order could shape the landscape of pharmaceutical pricing and availability in the U.S. for years to come.